The Federal Trade Commission has extended its antitrust review of Novo Holdings’ $16.5 billion purchase of Catalent by potentially another 30 days as it requests additional information.
Both the manufacturer and the Novo Nordisk Foundation, the parent company of Novo Holdings, were tapped by the FTC on Thursday for “additional information and documentary materials,” according to Catalent’s Friday SEC filing. Once both parties send the FTC the requested information, the agency will need a further 30 days to review.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.